This study will compare tenecteplase, a newer clot-busting drug, with alteplase, which is currently the routine treatment used in hospitals.
Thrombolysis, where drugs are injected into the blood to break up a blood clot, is one of the main treatments used to treat people who are having a stroke caused by a clot. Currently a drug called alteplase is used in thrombolysis. But the researchers think that another drug, called tenecteplase, may be more effective than alteplase. This study will investigate if this is the case.
You might be given blood-thinning medications after you've had a stroke, to help you avoid another one. Or you might need blood-thinning medication if you have a health condition such as a heart problem or blood-clotting disorder which could lead to a stroke.
A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
Exploring the effects of lowering blood pressure and a lower dose of clot busting drug on stroke outcome
The first day of the European Stroke Organisation Conference (ESOC) 2017 in Prague included some truly inspiring scientific sessions. These included reporting from the DAWN study which suggests that more patients could be able to receive mechanical thrombectomy after stroke.
Over 3500 delegates attended the 2nd European Stroke Organisation Conference (ESOC 2016) today in Barcelona. Today’s program included teaching courses, scientific presentations, an official welcome from the ESOC President Professor Kennedy Lees and from Professor Angel Chamorro, and presentations from major clinical trials.
The International Stroke Conference (ISC) 2018 took place in Los Angeles (24-26 January).
The ISC is the world's largest meeting dedicated to the science and treatment of stroke and its effects. Check out some of the highlights from 2018.
PRESS RELEASE - Issued by University of Leicester Press Office on Tuesday 10 May
University of Leicester involved in the international ENCHANTED trial to improve survival rates of stroke victims. Stroke Association funds UK arm of the trial.